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ABBREVIATIONS 
AUA   American Urological Association 
BPE  Benign Prostatic Enlargement  
BPH   Benign Prostatic Hyperplasia 
AUR  Acute urinary retention 
BOOI  Bladder outlet obstruction Index 
DRE   Digital Rectal Examination  
LUTS   Lower Urinary Tract symptoms  
TRUS   Transrectal Ultrasonography 
TAUS   Transabdominal Ultrasonography  
TPV  Total prostate volume 
TZV  Transitional zone volume 
TZI  Transitional zone index 
IPP / IPPV  Intravesical prostatic protrusion 
DWT  Detrusor wall thickness 
PVR  Postvoid residual 
PSA  Prostate specific antigen 
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     QoL  Quality Of Life 
     DHT  Dihydrotestosterone  
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INTRODUCTION 
 
Benign prostatic hyperplasia (BPH) is a very common urological 
condition affecting men in older age group. It occurs in about 10 % of men of 
the age of less than 40 years, and increased to 80 % in age group of 80. Even 
though there are other  causes now being considered, Benign prostatic 
hyperplasia still remains one of the most common cause  in men that can give 
rise  to lower urinary tract symptoms, with or without bladder outlet obstruction 
(BOO). It has been documented in a  multicenter study that the age-related 
division of men with symptoms was higher in the Asia Pacific when compared 
to the  Western countries  The reason behind this is unknown. 
 The pathological process in BPH is a hyperplasia (and not hypertrophy) which 
affects both the stromal and glandular elements of this gland. This condition 
affects the quality of life (QOL) in a significant way in many of the patients. 
 Even though most seek medical intervention because of bothersome 
symptoms, BOO was found in 60% in those symptomatic and 52% in those 
asymptomatic1, 2.  Lower urinary tract symptoms affect the patient’s quality of 
life.  Intervention may be needed for bothersome symptoms in around 30% of 
men who are older than 65 years 3. 
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Several theories have been proposed in the etiopathogenesis of BPH. 
These include  
- Age-related tissue changes,  
- Metabolic syndrome  
- Hormonal alterations,  
- Inflammation4.  
Although BPH is not caused by the androgens, the postulated theory is 
that the presence of androgens is needed for the pathogenesis. It should be borne 
in mind that the association between metabolic syndrome and the development 
of BPH exist. Recent evidences suggest that BPH may be due to an 
inflammatory-based disorder. 
For male older than 50 years of age, TURP is the second most common 
surgery performed next only to cataract surgery. Even though many new 
modalities of management for the BPH have been developed, TURP is still the 
gold standard as for as the management of BPH is concerned5. The development 
of LASERs in endourology is gradually replacing the TURP in the management 
of BPH. Holmium laser (HoLEP) is said to be the gold standard 6, 7 though 
many urologists have reservation in accepting this as the gold standard. The 
major disadvantage is the prohibitive cost of these lasers.  
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TURP still remains the widely used technique for the management of BPH8, 
9, 10 
TURP has become a relatively safer procedure due to the advent of newer 
technologies in diathermy and visual scopes. But still there is a chance of TURP 
syndrome and electrolyte imbalance especially in high-risk cardiac patients. The 
risk is accentuated by the use of glycine for irrigation. The complications rates 
were decreased with the development of bipolar diathermy with normal saline 
as irrigant fluid. 
Acute urinary retention 
Acute retention of urine is a severe symptom of men who developed 
BPH.  It is defined as a sudden and painful inability to void voluntarily 11, 12.  
Even though there are many causes of AUR, the most common cause being 
BPH. The prevalence rate of AUR in men with BPH is estimated to be as high 
as 53% 13 AUR is a painful condition. Higher mortality and morbidity rates in 
men presenting with AUR have been reported in previous studies 14, 15. 
In Western countries, AUR was the chief compliant in 20 – 42% of men 
who underwent TURP 16. Escalating postoperative complications and longer 
Hospital stays in men with BPH who develop AUR have been reported 15, 16, and 
17. Patients who presented with AUR had a high mortality rate in the first 3 
years after prostatectomy18. There are many studies available describing the 
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complications of BPH. Comprehensive comparative analysis of post-TURP 
complications between patients with and without AUR is lacking. 
In our study we tried to compare the post TURP complications between 
patients who presented with and without AUR 
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AIM OF STUDY 
 
 
 To compare the outcome and complications of TURP for BPH patients 
with and without acute urinary retention 
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REVIEW OF LITERATURE 
During the third month of fetal life the prostate begins to develop from 
the urogenital sinus. The development process is influenced primarily by the 
DHT. There are five epithelial buds on the posterior surface of the urogenital 
sinus which forms the prostate. This is present on either side of the 
verumontanum, which then invades the mesenchyme. The top buds are 
mesodermal in origin and it forms the inner zone and the lower buds are 
endodermal in origin which forms the outer zone.  This is very important as 
benign prostatic hyperplasia (BPH) develops from the inner zone whereas the 
carcinoma arises from the outer zone.  Around the urethra the inner and the 
outer zone develops as a concentric circle. On the outside of this zone the long 
branched ducts form the thick outer layer of the true prostate gland. The 
mucosal, sub mucosal gland, the ejaculatory ducts and the small remnants of the 
mullerian duct—the utriculusprostaticus, which forms the small prostatic utricle 
are present in the central region. By fourth month of fetal development the 
prostate is well differentiated .The acini and collecting ducts are formed in the 
prostate. During development the growth occurs primarily on the tips, as the 
ducts extend and branch. This concept that dynamic growth processes occur 
along a budding and branching system was developed from studies on the 
mouse and rat prostate 19 (Sugimura et al, 1986 ; Banerjee et al, 1993a, 1993b; 
Cunha, 1994 ). 
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The weight of a normal prostate gland is 18 grams. It has an anterior, 
posterior and lateral surface. The prostatic urethra traverses through the gland. 
The prostate has a narrow apex which is directed inferiorly and a broad base 
which is directed superiorly.24, 27. The gland is surrounded by a capsule which is 
composed of collagen, elastin, and smooth muscle. The average thickness of the 
capsule in the posterolateral aspect is 0.5mm. The plane between Denonvilliers' 
fascia and the rectum is defined by the loose areolar tissues. The capsule on the 
anterior and anterolateral surface blends with the endopelvic fascia. The apex of 
the gland is fixed to the pubic bone by puboprostatic ligament. 
 
Figure 1 Anatomy of Prostate gland 
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The pubococcygeal portion of levatorani muscle covers it and is related to 
its endopelvic fascia in the lateral aspect. Below is the Myers lateral 
endoprostatic fascia.21, 22. The neurovascular bundle runs posterolaterally 
towards the prostate in the lateral prostatic fascia. 
The apex of the prostate is continuous with the rhabdosphincter28, 29. 
Histology reveals that the normal prostatic glands extend into the 
rhabdosphincter and there is no intervening capsule between the prostatic apex 
and the rhabdosphincter. 
Structure of the prostate  
Prostate is composed of 70% glandular elements and 30% fibro muscular 
stroma. The fibro muscular stroma encircles the glandular elements of the 
prostate When it contracts during ejaculation it will express prostatic secretions 
into the urethra. 
ZONAL ANATOMY23 
1. The five lobes of the prostate can be seen before twenty weeks of 
intrauterine life. 
2. Out of the five lobes, 3 lobes are recognizable- 2 lateral and a median 
lobes  
3. From a pathological point of view, the glandular tissue is subdivided into 
3 distinct zones.  
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1) Peripheral (70% by volume)-PZ  
2) Central (25% by volume)-CZ  
3) Transition (5% by volume)-TZ  
4. Fibro muscular stroma of the prostate occupies the space between the 
peripheral zones that are anterior to the preprostatic urethra.  
5. The CZ is posterior to the preprostatic urethra and is conical in shape. It 
is traversed by the ejaculatory duct. 
6. Mucus secreting glands are present in the tissue which surrounds the 
preprostatic urethra  
7. The pathological process rarely affects the CZ as its histological 
properties are different from the rest of the prostate. The CZ is thought to 
be a derivative of the Wolffian duct system (Like that of the epididymis, 
vasa differentia and seminal vesicles) 
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Figure 2 Zonal Anatomy of Prostate 
On clinical examination the prostate is described as having two lateral 
lobes and a median lobe.  The central sulcus which separates the two lateral 
lobes will be palpable on per rectal examination.  
ETIOPATHOGENESIS OF BPH 
Many theories have been postulated in the pathogenesis of BPH. 
• The androgen acts via the receptors and induces the development 
of prostate.  
• In adults the quiescence state of the prostate is maintained by the 
homeostatic mechanisms between stroma and epithelium. 
11 
 
•  Even though DHT is the primary growth hormone for prostate, its 
level is not elevated with human BPH30. The paradoxical 
observation of development of BPH despite declining levels of 
androgen denotes that secretion of other factors may be the reason 
behind this31.  
• Estrogens along with other hormones may cause benign prostatic 
hyperplasia. Sometimes it may leads to the development of 
neoplasia, and dysplasia32, 33, 34.  
 
 
 
 
 
 
 
Figure 3 Pathogenesis of BPH 
 
 
Cunha et al19, 32 described that the stroma is responsible for the 
modulation of the differentiation pattern of prostatic epithelium. Abnormal 
peptide factors are also implicated in this process. The “stromal cell” is the key 
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cell as many growth factors are secreted by these stroma cells. These growth 
factors act on the cells and leads to the development of BPH 
There are many qualitative as well as quantitative changes that occur in 
the extracellular matrix. The exact role played by the glycosaminoglycans and 
epidermal growth factor is under study35  
Infection has its own role to play in the pathogenesis of BPH 36. Many 
literatures which describe the pathogenesis of BPH have suggested that 
inflammation does have a definitive role to play 37, 38, 39, 40, and 41. Kramer and 
Marberger 41 have described the recent concepts of the role of inflammation.  
Growth of the fibro muscular stroma is supported by the production of 
cytokines (IL-2 and IFNγ) 41. Surrounding cells die, and the empty spaces will 
be occupied by nodules.  
Familial association for BPH has been described by Sands et al (1994) 
and Robert et al (1997) 
Pathophysiology of BOO 
Many terms are in use to describe and quantify the bladder and lower 
urinary tract symptoms due to prostate enlargement. No single symptom is 
singularly representative of BPH. Stricture urethra, function of the detrusor 
muscle and the CNS function all will interact to produce lower urinary tract 
symptoms. These symptoms were historically described as ‘prostatism’.  
The following are the mechanisms by which Benign prostatic hyperplasia 
(BPH) may cause obstruction:-  
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• Ball wall mechanism caused by the large median lobe enlargement 
• A dynamic obstruction due  to the contractile effect of the prostatic 
smooth muscle 
• A static obstruction due to the enlarged prostate which envelopes 
the prostatic urethra, or a restricted surgical capsule.  
 
Each one of the above said mechanisms is clinically feasible and 
components of each are likely to be present in most of the cases. As a result of 
which there will be an increased intravesical pressure and a reduction in flow, 
which ends up in gradual development of secondary changes in the muscle. 
Histological Features 
Benign prostatic hypertrophy is a misnomer because there is only 
hyperplasia and not a hypertrophy. This fact has been illustrated by McNeal in 
his histological study.  McNeal’s studies demonstrated that most of early 
periurethral nodules were purely stromal in character25.  
BPH in its early stage of its development is characterized by an increase 
in the number of nodules. The growth of each new nodule is generally very 
slow24, 25 (McNeal, 1990). During the secondary phase there is a growth of cells 
in large nodules. 
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There is pleomorphism in the stromal-epithelial tissues ratio. Fibro 
muscular stroma predominates in the smaller glands42 (Shapiro et al, 1992b) 
whereas epithelial nodules predominates in the larger glands43 (Franks, 1976).  
Importance of Prostatic Smooth Muscle  
Major portion of the enlarged gland is composed of prostatic smooth 
muscle42 Shapiro et al, 1992a). There are both active and passive forces which 
present in and around prostatic tissue play a major role in the pathophysiology 
of BPH43 (Shapiro et al, 1992), All these will leads to a mechanical and 
dynamic outlet obstruction.  α-Adrenergic blockade results in significant down 
regulation of smooth muscle myosin heavy chain which will leads to a decrease 
in dynamic obstruction44 (Lin et al, 2001). 
Effect of obstruction on the bladder:  
Alteration in the gross anatomical, histological, cellular and molecular 
aspects in the bladder wall, because of outlet obstruction impairs its function 
and adds to the symptomatology of BPH45. Early phases of outflow obstruction 
are compensated by the detrusor muscle Hypertrophy. When the obstruction is 
chronic there will be decreased compliance of the detrusor and impaired 
emptying. This occurs due to the deposition of extracellular matrix (ECM) 46. 
During this process acute urinary retention may occur and may be either due to 
the bladder failure, as well as due to a sudden increase in outflow obstruction. 
The alteration in ECM is probably the most common pathophysiological feature 
15 
 
in chronic obstruction. Experimental Studies from the rabbit model have shown 
that significant smooth muscle hyperplasia is induced whenever the load is 
increased and that this is will be associated with down regulation of myosin 
light chain (MLC) expression. This effect contributes to the decreased smooth 
muscle contractility 47. 
 
 
Figure 4: The Pathophysiology of BOO 
 
Lower Urinary Tract Function of Ageing 
Due to the process of ageing there will be CNS effects and changes in 
adjacent organ systems which may   increase LUTS 48.  
The degree of the prostatic enlargement does not always correlate with 
the LUTS. 
There are some drugs which induce LUTS in some individuals with a normal 
lower urinary tract49. Severe bothersome symptoms, dysfunction of the urinary 
bladder, urinary tract infection, CKD etc are the clinical end points. Olmstead 
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County Study gave us insights regarding the natural progression of benign 
prostatic enlargement49. 
Lower Urinary Tract Symptoms 
The nomenclature used to describe voiding dysfunction in aging men is 
quiet confusing and often inaccurate50. The term BPH should be used with 
reference to the histological process of hyperplasia.  In patients with benign 
prostatic enlargement (BPE) there will be an increase in total prostate volume 
because of BPH. Enlargement of prostate may or may not produce clinically 
significant LUTS and the BPE may or may not produce features of bladder 
outlet obstruction. 
Lower urinary tract symptoms (LUTS) is the current most commonly 
accepted terminology for urinary symptoms 50. According to the International 
Continence Society (ICS), LUTS means:  
- A symptom, - Which is perceived by the subject51 
- A sign – which is observed by the physician 51 
- A condition – which is defined by urodynamic evaluations 51 
 
Abrams et al classifications of LUTS:- 
He classified the symptoms into three categories which were incorporated 
in the ICS system:  
- Storage symptoms -  Symptoms which occurs during the filling 
phase 
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- Voiding symptoms - Problems during voiding. 
- Post micturition symptoms – Symptoms which occurs immediately 
after micturition. 
Prediction of Bladder Outlet Obstruction: 
Tools which are used to evaluate the degree of BOO due to BPH 
o Symptom Scores / QoL 
o Prostate volume 
o Qmax 
o Bladder outlet obstruction index / Bladder contractility Index 
o Post void Residual urine 
o PSA 
All the above said parameters neither by themselves nor in combinations were 
very predictive of the need for surgery in BPH patients.  
USG parameters to assess the BOO  
• Total prostate volume 
• Transitional zone volume 
• Transitional zone index 
• Intravesical prostatic protrusion 
• Resistive index 
• Detrusor wall thickness 
• Ultrasonic estimation of bladder weight. 
Management of BPH 
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Even though many alternative techniques have been introduced for the 
management of BPH, TURP is still the generally accepted procedure of choice 
for BPH.  Advancement in the technology has reduced the complication rates 
for the past few years. 
Indications for TURP 
- Recurrent UTI caused by BOO 
- Recurrent episodes of urinary retention 
- Bladder calculi 
 -Recurrent haematuria  
- Renal insufficiency caused by BPH 
Various techniques have been described for the resection of prostate. Monopolar 
and bipolar current can be used.  The irrigation fluid for the bipolar is normal 
saline. Complications rates have been said to be decreased with resection in 
saline using bipolar. 
Laser prostatectomy 
Other alternative technologies used for the ablation of prostate is using of 
laser for resection. The main advantages of this technique are it provides a 
virtually bloodless field and also the post surgical catheterization time is short 
with functional outcomes that are comparable with TURP. 
Intra-operative complications 
Technical difficulties are the main reasons for these intraoperative 
complications  
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Bleeding 
Arterial bleeding will be more for patients with preoperative infection or 
urinary retention, because the gland will be congested. Treatment with anti-
androgen like finasteride or flutamide may reduce bleeding. Whenever there is 
capsular perforation or opening of the venous sinusoids, there will be profuse 
venous bleeding. The gland size and resection weight may dictate the amount of 
bleeding 
Management of bleeding 
Coagulation of bleeders is very important in TURP surgery. Irrigation 
fluid returning should be glistening pink in colour. Bleeding from arteries will 
be bright red in colour; in that case we should reintroduce the resectoscope and 
coagulate the bleeding points completely. Bleeding from the small veins can be 
controlled with Foleys balloon with traction. 
TUR syndrome can occur especially if we are doing resection using monopolar 
with water or glycine as irrigant. It should be promptly diagnosed and treated 
appropriately. 
Extravasations 
Extravasations can occur if there is capsular breach with elevation of 
trigone of the bladder. For extra peritoneal extravasations, mere placement of 
catheter drainage is sufficient. Intraperitonal extravasations should be drained or 
sometimes surgery may be needed. 
Injury of orifices 
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During resection of large mid-lobes there is always a chance of injuring 
the ureteric orifice. The management of ureteric orifice injury depends on the 
extent and nature of injury. 
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Complications of TURP 
 
 
Early  
Periods  
Authors Numbers Transfusion Rate (%) 
Revision 
Rate (%) 
Infection 
Rate (%) 
TUR 
syndrome 
(%) 
Zwergel 
et al 1979 232 21.2 NA NA 1.6 
Mebust 
1989 3885 6.4 NA 2.3 2 
Doll 1992 388 22 3 14 NA 
 
 
 
 
 
 
Inter 
mediate 
periods 
 
Authors Numbers Transfusion (%) 
Revision 
(%) 
Infection 
(%) 
TUR 
syndro
me (%) 
Zwergel 
1995 214 14.6 NA NA 0.8 
Horninger 
1996 1211 7.6 NA NA 2.8 
Haupt1997 934 2.2 NA NA 0.3 
Gallucci 
1998 80 0 NA 5 0 
Gilling 
1999 59 6.6 3.3 8.2 0 
 
 
 
 
 
Recent 
Periods  
Authors Numbers Transfusion (%) 
Revision 
(%) 
Infection 
(%) 
TUR 
syndrome 
(%) 
Heilbronn 
2003 126 4.8 4.2 1.7 0.8 
Banden 
2003 7707 3 5 3.5 0.8 
Kuntz 2004 100 2 3 4 0 
Berger 2004 271 2.6 NA NA 1.1 
 
NA = not available. 
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Perioperative complications 
Studies done in early periods 
 
Complications 
Rate In % 
Mebust et al Doll et al 
Clot retention 
Rate  
3.3 11 
Bleeding and transfusion 
rate  
6.4 22 
TUR syndrome 2 NA 
Capsular perforation 
Rate 
0.9 10 
HN 0.3 NA 
Infection 3.9 25 
Sepsis 0.2 3 
Retention  6.5 3 
Incontinence NA 38 
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Studies done in intermediate periods 
Complications 
In % 
Haupt  et al Borboroglu et al 
Clot retention rate 1.9 1.3 
Bleeding and transfusion rate 2.2 0.4 
TUR syndrome 0.3 0.8 
Capsular perforation rate NA NA 
HN 0 0 
Infection  1.6 4 
Sepsis  0.2 0 
Retention  NA 7.1 
Incontinence 0.3 NA 
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Study done in recent periods 
Complications 
In % 
Kuntz et al 
Clot retention Rate  5 
Bleeding and transfusion rate 2 
TUR syndrome 0 
Capsular perforation 4 
HN 0 
Infection  4 
Sepsis  0 
Retention  5 
Incontinence 1 
 
Bladder tamponade 
Clot formations can occur due to recurrent or persistent bleeding which 
may lead to bladder tamponade that require evacuation or even re intervention 
(1.3–5%). 
Intermittent change of colour in the irrigation outflow indicates that the 
bleeding is arterial in origin. Whereas dark red continuous flow in irrigant fluid 
return indicates venous origin  
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Management 
Acute retention of urine due to clots should be evacuated emergently.  
Then a 3 way foley balloon inflated 20 cc more than the weight of the resected 
tissue and traction is given. If the return is not clear, the patient should be 
immediately posted for reintervention with clot evacuation and coagulation of 
the bleeding points. In these patients bleeding may be stopped by recto-digital 
compression. If the above mentioned maneuvers does not work then Trans 
femoral super selective embolization can be done 52 
Incontinence 
In around 30-40% of cases there may some early incontinence after the 
TURP, which will get resolved in due course. Only in less than 0.5% of patients 
there will be persistence of urinary incontinence. 
Early management 
Patients should be carefully evaluated if there is incontinence.  
This may be due to either one of the following reasons  
1) Irritative symptoms such as due to fossa healing  
2) Associated UTI  
3) Detrusor instability caused by long-lasting BPH 
Patients can be treated with for symptomatic relief with anticholinergic 
medications. 
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Urodynamic evaluation 
If the incontinence persists for more than six months thorough 
investigation has to be done. The patient should be subjected to AUG, 
diagnostic cystoscopy, and UDE.  
Causes of incontinence 53, 54  
-Sphincter incompetence (30%),  
-Detrusor instability (20%),  
-Mixed incontinence (30%),  
-Residual adenoma (5%), 
-Bladder neck contracture (5%), and  
-Urethral stricture (5%). 
Late management 
Exercise to the pelvic floor muscle. Medical management with duloxetine 
can be tried. Artificial sphincter is the last option if other methods fail. 
Urethral stricture 
Urethral stricture can occur if larger instruments are used and if there is 
history of prolonged catheterization. Strictures at the bulbar region occur due to 
the leakage of monopolar current because of insufficient isolation by the 
lubricant. We have to apply gel in the urethra as well as in the shaft of 
resectoscope. We should avoid high cutting current. If there is stricture at the 
meatus or urethra it should be dealt with internal urethrotomy before TURP  
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Bladder neck stenosis 
Bladder neck stenosis occurs at the rate of 0.3% to 9.2%. This will occur 
usually when resection is done for smaller glands (<30 g). TURP should be 
avoided for smaller glands  
Retrograde ejaculation 
Retrograde ejaculation occurs in most of the patients (53–75%) who 
underwent TURP.  So while treating a younger patient with BPH, it is better to 
try with medical management, or a TUIP. 
Jeng-Sheng Chen et al conducted a retrospective national, population 
based study in Taiwan to compare the Post TURP outcome for patients who 
presented with and without AUR. They included men over 50 years of age with 
the diagnosis of BPH and allocated them into two groups, those with and 
without AUR. They excluded patients with Parkinsonism disease, prostate 
cancer, and patients with features suggestive of neurogenic disease. They 
compared the complications occurred between these two groups after the TURP.  
The assed the intra operative and post operative complications and outcomes 
like, haematuria, need of blood transfusion, UTI as evidenced by the urine 
culture, septicemia, antibiotic use, mean length of hospitalization, need for 
recatheterisation, post operative stricture and the need for resurgery  and the 
medical expenses. 
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Comparison of  Post TURP complications between patients with and 
without retention  
Sr no Variables With AUR 
% 
Without 
AUR % 
P value 
1 Recatheterisation 13.8 0 <0.001 
2 Haematuria 8.1 7.4 0.46 
3 UTI 18.9 15.6 0.01 
4 Stricture 2.6 3.2 0.32 
5 Resurgery 1 1.3 0.38 
6 LUTS 22.8 16.9 <0.001 
7 Sepsis 1.1 0 <0.001 
8 Blood 
transfusion 
3.2 1.5 0.004 
9 Antibiotics 0.9 0.7 0.49 
10 Length of stay 6.4 4.6 <0.001 
 
In their study the recatheterisation rate were 13.8% in AUR group where 
as it was nil in patients without AUR which is significant with a P value of 
<0.001. Haematuria occurs in 8.1% in patients with AUR and 7.4% in patients 
without AUR.  This is not statistically significant. UTI occurred post 
operatively in 18.9% for patients with AUR, where as it was 15.6% in patients 
without AUR with a P value of 0.01 which was significant. Lower urinary tract 
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stricture was 2.6%vs3.2% for patients with and without AUR respectively, 
which is not statistically significant with a p value of 0.32. Regarding resurgery, 
it was 1% in AUR group and 1.3% in AUR minus group. LUTS such as 
increased frequency, dysuria and incontinence were 22.8% in AUR group where 
as it was 16.9% in AUR minus group with a p value of <0.01 which was 
significant. Sepsis occurred in 1.1% in AUR group where as it was nil in AUR 
minus group with a p value of <0.001.Need for blood transfusion was 3.2% in 
AUR group and 1.5% in AUR minus group with a p value of 0.004 which was 
significant. Mean   length of hospital stay and mean medical expenses was 
statistically significant in AUR group when compared to AUR minus group. 
They concluded that patients who present with AUR developed more 
complications than patients without AUR. 
In their study, recatheterisation rate was nil in patients without AUR, 
which showed that detrusor contraction function was injured after urinary 
retention. 
Jeng-Sheng chen et al study from Taiwan showed that recatheterisation 
rate, Haematuria, UTI,  LUTS, sepsis, blood transfusion, second line antibiotic 
use, mean hospital stay and mean medical expenses were increased for patients 
with AUR when compared to patients without AUR. Of these variables 
recatheterisation, UTI, LUTS, sepsis, shock, blood transfusion, mean length 
hospitalization and medical expenditure were statistically significant for patients 
who presented with AUR. 
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Pickard et al study (6) showed, the urinary infection occurs in around 
18.6% of the patients who underwent TURP. . In Doll et al study it was quiet 
higher – 25%. The higher recatheterisation rate may also be the reason for 
increased UTI in patients with AUR. 
Urethral stricture rate reported in literature ranges between 2.2 to 9.8%.  
It was theoretically explained that the reason for increased rate of stricture in 
AUR group may be due to increased catheterization and increased number 
UTIs. Surgical technique, the size of the instrument used for TURP and the 
lubricant usage should also be taken into account for stricture formation. 
Literature reported the resurgery rate after TURP between 3 – 14.5%. The 
reasons quoted for the re-surgery were blood clot tamponade, torrent bleeding, 
and inadequate resection 
Incontinence  
Haupt et al reported incontinence rate as 0.3%. Kuntz showed 1%. It was 
higher in Doll et al who reported 38%.   Even though the IPSS was higher in the 
immediate post operative period it will decrease over a period of time. 
Regarding the lengthy hospital stay and increased medical expenses, the 
reason may be the associated comorbid factors for patients with AUR 
Sajjad Ahmed et al from Lady Reading hospital Peshawar conducted a 
study to compare the complications between patients with and without AUR 
who underwent TURP. In their study 48% presented with AUR and 52% 
presented without AUR. In their study they concluded that the complications 
rate were higher in patients who presented with AUR. 
  
  
 
 
MATERIALS  AND 
METHODS 
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MATERIALS AND METHODS 
 
1. Study group: 
Patients who were admitted in Kilpauk Medical College and Govt. 
Royapettah Hospital with lower urinary tract symptoms (LUTS) due to benign 
prostatic hyperplasia (BPH) with and without acute urinary retention are 
included in the study. 
2.  Study design: Prospective observational analytic study 
3.  Study period: One year from 01.01.2014 to 31.12.2014 
4. Materials: 
The patients with complaints suggestive of LUTS were thoroughly 
evaluated with History & Physical examination, DRE, USG KUB, Uroflow& 
PVR and patients with BPH were selected.  Patients who presented with and 
without AUR were assigned as group A and Group B respectively 
Inclusion criteria – 
1) Prostate sizes > 30gms and less than 60 gms 
2) Maximum flow rate (Qmax) less than 10 ml/s, 
3) Men more than 45years and less than 70 years 
4) Post void residual urine (PVR) exceeding 100 ml, 
5) Patients who gave informed consent for the study were included 
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Exclusion criteria – 
1. Urethral stricture, 
2. Neurogenic bladder, and 
3. Previous prostate or urethral surgery 
4. Unwilling patients 
5. Prostate cancer 
This is a prospective analytical study conducted in both Kilpauk Medical 
College Hospital and Government Royapettah hospital from January 2014 to 
December 2014. 
The ethical committee of this institution has given approval to conduct this 
study. All men who participated in this study have given written consent for this 
study. Totally 126 patients were enrolled in this study, of which 74 were 
patients presented with AUR and 52 were patients who presented without AUR. 
The diagnosis   of BPH was confirmed both by clinical evaluation and by 
radiological method. Patient age, associated comorbid conditions, was recorded. 
IPSS grading system was used to assess the patient symptoms. It consists of 7 
symptoms with score of 0 to 5 for each symptoms and the total maximum score 
is 35.  Low grade is - 0 to 7. Moderate grade- 8 to 19 and high grade 20 to 35. 
Based on this patients with moderate to high grade may need interventions. For 
patients who presented with AUR, urinary symptoms prior to AUR were 
recorded. 
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DRE: - Digital rectal examination was done to assess the grade as well as the 
consistency, symmetry of the gland, any obliteration of median furrow and 
lateral sulci, and also presence of any nodules were assessed. It was done under 
local anesthesia with the patient in left lateral position. BPH was graded, 
depending on the encroachment of the prostate into the rectal lumen. 
DRE grading of prostate 
Size DRE 
Normal Encroaches 0 to 1 cm into rectal lumen 
I 1 to 2cm 
II 2 to 3 cm 
III 3 to 4 cm 
IV >4 cm 
 
Basic blood investigations like complete haemogram, renal function test, 
random blood sugar, serum electrolytes were done before the procedure. Serum 
electrolytes were done in all the patients after the procedure and during surgery 
if the clinical picture suggestive of TUR syndrome. Only one patient in the 
AUR group developed TUR syndrome which was diagnosed and corrected 
promptly. 
Routine urine analysis and urine culture were done in all the patients.  
Urine culture was done by collecting the mid stream voided urine in patients 
without AUR. For patients with AUR urine sample was collected from urethral 
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catheter. If culture was found to be positive appropriate antibody was given and 
UTI treated before the procedure. Urine culture was also done in all the patients 
after the procedure. 
Serum PSA was measured in all the patients who have enrolled in this 
study. If the patients presented with catheter, serum PSA was done one week 
later. If the PSA was in the gray zone, or if the percentage of free PSA was low, 
TRUS followed by biopsy was done to rule out malignancy. If the patient was 
found to be positive for malignancy he was excluded from the study. 
Uroflowmetry was done in all the patients as an outpatient procedure to 
assess the flow pattern. If stricture pattern was found during the Uroflow 
evaluation, ascending urothrogram was done to rule out stricture. If the Uroflow 
findings does not correlates with the clinical examination , or if there is any 
suspicion of neurogenic bladder, urodynamic  evaluation was done to rule out 
any neurogenic component. Patients with neurogenic problems were excluded 
from the study. 
AHCPR guidelines of Uroflowmetry 
 If voided volume is < 125 to 150 ml, the measurements are 
inaccurate. 
 This is the single best non-invasive urodynamic test to detect the 
BOO, but there is no cut off value 
 Q max identifies patients with BPH than Qave 
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 Patients with Q max >15ml/sec appear to have poorer outcome  
than patients with Qmax  <15ml/sec after surgery 
 Q max < 15ml/sec will not differentiate between patients with 
obstruction and bladder decompensation. 
Uroflow assessment was done in all patients after surgery to compare and 
analyze the outcome 
 
Normal Uroflowmetry showing bell shaped curve 
USG  KUB  
We did USG for all the patients mostly transabdominal to measure the 
prostate size and  to assess the PVR. USG were done in all the patients 
postoperatively also to measure the PVR.  
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METHODS OF ESTIMATING THE PROSTATE SIZE 
Size can be estimated either by transabdominal, transrectal, or 
transperineal USG. As the specific gravity of the gland and that of water are the 
same, volume is roughly equivalent to weight of prostate i.e. 1 cm3 equals 
approximately 1 gram of prostate tissue. 
The following dimension are required to calculate the prostate volume 
- Axial plane - Anteroposterior dimension and the transverse 
dimensions. 
- Sagittal plane - Longitudinal dimension (measured just off the 
midline) 
Most formulas were devised assuming that the gland conforms to an ideal 
geometric shape, i.e. 
• Ellipse= π  /6 x TS x AP x CC,  
• Sphere= π /6 x TS3 ,  
• Prolate (egg shape) / spheroid = π 6 x TS2 x AP.  
The prolate ellipsoid method calculates the volume by using the 
following formula: 
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Transverse diameter x Anteroposterior diameter x Length x 0.52. 
 
Axial plane - Anteroposterior dimension and the transverse dimensions. 
USG should be done in the full bladder so that prostate will be clearly 
delineated. USG has been done in the axial plane which shows the prostatic 
enlargement. 
Antero-posterior and transverse dimensions of the prostate are recorded 
in this axial plane 
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Sagittal plane - Longitudinal dimension (measured just off the midline) 
This picture shows USG done in the sagittal plane. Longitudinal 
dimension of the prostate is recorded in this plane 
 
 
TRUS image of prostate 
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Procedure performed - TURP 
Surgical therapy was mainly Transurethral resection of prostate (TURP). 
Procedure was done using monopolar current under spinal anesthesia. With the 
patient in lithotomy position, we do cystoscopy and assess the prostate grade 
and inspect the bladder for growth, stone and any signs of obstructions are seen. 
Resection was done using 24 fr Baumrucker resectoscope. We used water as 
irrigant fluid. At the end of the procedure coagulation was achieved and 22 fr 3 
way Foleys catheterization done in all cases and irrigation started.  We apply 
traction for all cases. Catheter will be removed for all the cases on 3rd or 4th post 
operative day. If the patient develops retention after catheter removal, we will 
recatheterise the patient and advised him to take alpha blocker and come for 
review after 1 week and give trial void. 
Post operative variables (PVR, Uroflowmetry parameters) were 
compared. Post operative complications like urinary tract infection, sepsis, 
haematuria, blood transfusion, post operative LUTS, recatheterisation, length of 
hospital stay, stricture, and resurgery were recorded 
 
 
 
 
 
 
  
 
 
OBSERVATION 
AND RESULTS 
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OBSERVATION AND RESULTS 
The aim of our study was to compare the outcome and complications of 
post TURP between patients who presented with and without AUR.  We 
compared the following factors of preoperative variables like age, presence of 
any co morbid illness, gland size, grade of the gland by DRE, serum PSA.  And 
post operative variables like haematuria, need for blood transfusion, UTI, 
sepsis, recatheterisation rate, post operative irritative LUTS, PVR, length of 
hospital stay, lower urinary tract stricture , re surgery rate, TUR syndrome, Q 
max. 
We enrolled 126 patients, out of which 74 were in AUR group and 52 in 
AUR minus group. We excluded patients with neurogenic illness, prostatic 
carcinoma. All patients were followed for a period of three months. 
Statistical Methods: Summary statistics mean, standard deviation and 
percentage for the groups were computed. Chi-square test has been used to find 
the significance of study parameters on categorical scale between two groups. 
Results on continuous measurements are presented on Mean ± SD... Student‘t’ 
test i.e. independent t-test has been used to determine the statistical significance 
between two group means. All analyses were two tailed and p <0.05 was 
considered significant. SPSS version 16.0 was used for data analysis 
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1 Age Distribution 
 
 
 
In our study out of 126 patients, 34.9% belongs to less than 60 years and 
34.1% between 61 and 65 years, and 31% of patients are more than 65 years. 
 
 
 
 
 
 
 
34.9 
34.1 
31.0 
Age distribution 
<60 yrs 60-65 >65 yrs
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In No AUR group 36.50% of patients were less than 60 years of age, 
36.50% were between 60 and 65 years, 26.90% were more than 65. 
In AUR group 33.80% were below 65, 32.40% were between 60 and 65, 
33.80% were more than 65. 
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Table 1 
 
 Group N Mean Std. Deviation P-value 
Age 
AUR 74 62.51 5.377 
0.164 
Non_AUR 52 61.06 6.242 
 
  Frequency Percent 
Valid 
<60 yrs 44 34.9 
60-65 43 34.1 
>65 yrs 39 31.0 
Total 126 100.0 
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Group * Age group Cross tabulation 
 
Age group 
Total 
<60 yrs 60-65 >65 yrs 
Group 
AUR 
Count 25 24 25 74 
% within 
Group 
33.8% 32.4% 33.8% 100.0% 
Non_AU
R 
Count 19 19 14 52 
% within 
Group 
36.5% 36.5% 26.9% 100.0% 
Total 
Count 44 43 39 126 
% within 
Group 
34.9% 34.1% 31.0% 100.0% 
 
P value – 0.711. It is not significant. So both groups are comparable with 
age. The mean age for patients with AUR is 62.51 and that for patients without 
AUR is 61.06 
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Table 2 Hypertension 
 No Yes Total 
With AUR 58 16 74 
Without AUR 42 10 52 
Total 100 26 126 
 
Chart 2. HT 
 
 
In our study 21.6% of patients with AUR had HT and 19.2% of patients 
without AUR had HT 
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Cross tabulation- HT 
  
                  HT Total 
 NO YES 
Group 
AUR 
Count 58 16 74 
% 78.4% 21.6% 100.00% 
Non AUR 
Count 42 10 52 
%   80.8% 19.2% 100.00% 
Total 100 26 126 
Percentage 79.4% 20.6% 100.00% 
 
Chi square test 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .107a 1 .744   
Continuity 
Correctionb .011 1 .918 
  
Likelihood Ratio .107 1 .743   
Fisher's Exact Test    .825 .462 
inear-by-Linear 
Association .106 1 .745 
  
N of Valid Casesb 126     
 
P value – 0.918 P value is not significant and hence both groups are 
comparable in relation to the hypertension 
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Table 3 Diabetes mellitus 
 No Yes Total 
With AUR 57 17 74 
Without AUR 40 12 52 
Total 97 29 126 
 
Chart 3. Diabetes mellitus 
 
In our study 23.0% of patients who presented with acute urinary retention 
had DM as comorbid condition and 23.1% of patients without AUR had DM, 
almost both groups are same 
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DM group-Cross tabulation 
  
DM Total 
 NO YES 
Group 
AUR 
Count 57 17 74 
% 77.00% 23.00% 100.00% 
Non 
AUR 
Count 40 12 52 
%   76.90% 23.10% 100.00% 
Total 97 29 126 
Percentage 77.00% 23.00% 100.00% 
 
Statistics 
 
Value Df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .000a 1 .989   
Continuity Correctionb .000 1 1.000   
Likelihood Ratio .000 1 .989   
Fisher's Exact Test    1.000 .577 
Linear-by-Linear 
Association .000 1 .989 
  
N of Valid Casesb 126     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 
11.97. 
b. Computed only for a 2x2 
table 
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P value 1.000. There was no statistical significance as the p value is 1.000 
and so the two groups are comparable in relation to the DM. so in our study the 
DM status has not affected the comparison 
Table 4 IHD 
 No Yes Total 
With AUR 66 8 74 
Without AUR 47 5 52 
Total 113 13 126 
 
Chart4. IHD 
 
In our study 10.8% of patients with AUR suffered from IHD, whereas 
9.6% of patients without AUR had IHD. If the patient was on any antiplatelet 
drugs, we will ask them to stop one week before the procedure 
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IHD group –Cross tabulation 
  IHD Total  NO YES 
Group 
AUR 
Count 66 8 74 
% 89.2% 10.8% 100.0% 
Non AUR 
Count 47 5 52 
%   90.4% 9.6% 100.0% 
Total 113 13 126 
Percentage 89.7% 10.3% 100% 
 
Statistics 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .047a 1 .828   
Continuity 
Correctionb .000 1 1.000 
  
Likelihood Ratio .047 1 .828   
Fisher's Exact Test    1.000 .537 
 
P value – 1.000 There was no statistical significance as the p value is 
1.000 and so the two groups are comparable in relation to the IHD. 
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Table 5 DRE 
 Grade I Grade II Grade III Total 
With AUR 7 66 1 74 
Without AUR 21 31 0 52 
Total 28 97 1 126 
 
Chart 5. DRE 
 
Regarding the grading of prostate by DRE, 9.5% of patients with AUR 
and 40.4% without AUR had grade I enlargement. 89.2% with AUR and 59.6% 
without AUR had grade II enlargement. 1.4% with AUR and no patients in 
AUR minus group had grade III enlargement 
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Cross tabulation - DRE grading 
   DRE Total  Grade I  Grade II Grade III 
Group 
AUR 
Count 7  66 1 74 
% 9.5%  89.2% 1.4% 100.0% 
Non 
AUR 
Count 21  31 0 52 
%   40.4%  59.6% 0% 100.0% 
Total 28  97 1 126 
Percentage 22.2%  77.0% 0.8% 100% 
 
Chi-Square Tests 
 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 17.315a 2 .000 
Likelihood Ratio 17.769 2 .000 
Linear-by-Linear 
Association 
17.131 1 .000 
N of Valid Cases 126   
 
P value 0.000 In our study most of the patients with AUR had grade II 
enlargement of the prostate. In patients without AUR, they had both grade I and 
grade II enlargement with grade II outnumbered grade I 
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Table 6 Volume and serum PSA 
Group statistics of volume and serum PSA  
Student T test 
 Group N Mean Std. Deviation P-value 
Volume 
CC 
AUR 74 53.20 4.382 
0.000 
Non_AUR 52 44.21 5.211 
PSA   
AUR 74 3.357 .4863 
0.006 
Non_AUR 52 3.094 .5731 
 
Volume of the gland, serum PSA level was statistically significant in our 
study as evidenced by the p value. 
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Table 7 TUR syndrome 
 No Yes Total 
With AUR 73 1 74 
Without AUR 52 0 52 
Total 125 1 126 
 
Chart 7 TUR syndrome 
 
 
Only one patient in AUR group developed TUR syndrome 
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TUR syndrome group 
Cross tabulation 
 
TUR syndrome 
Total 
NO YES 
Group 
AUR 
Count 73 1 74 
% within 
Group 98.6% 1.4% 100.0% 
Non_AU
R 
Count 52 0 52 
% within 
Group 100.0% .0% 100.0% 
Total 
Count 125 1 126 
% within 
Group 99.2% .8% 100.0% 
 
P value – 1.00 
TUR syndrome occurred only in one patient in AUR group at the end of 
surgery. Serum electrolytes were done which showed dilutional hyponatremia.  
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Table 8 Haematuria 
 No Yes Total 
With AUR 66 8 74 
Without AUR 49 3 52 
Total 115 11 126 
 
Chart 8. Haematuria 
 
In our study 10.8% of patients who presented with AUR had persistent 
haematuria after TURP, whereas 5.8% of patients without AUR had haematuria 
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Haematuria group - Cross tabulation 
  Haematuria Total  NO YES 
Group 
AUR 
Count 66 8 74 
% 89.2% 10.8% 100.0% 
Non AUR 
Count 49 3 52 
% 94.2% 5.8% 100.0% 
Total 115 11 126 
Percentage 91.3% 8.7% 100% 
  
Statistics  
 Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .974a 1 .324   
Continuity Correctionb .444 1 .505   
Likelihood Ratio 1.020 1 .313   
Fisher's Exact Test    .523 .257 
Linear-by-Linear 
Association .966 1 .326   
N of Valid Casesb 126     
  
P value 0.523 
After TURP 10.8% of the patients who presented with acute urinary 
retention had persistent haematuria, where was in the AUR minus group 
only5.8% had significant haematuria. Haematuria is not statistically significant 
in AUR group as evidenced by the P value of 0.523 
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Table 9 Blood transfusion 
 No Yes Total 
With AUR 71 3 74 
Without AUR 51 1 52 
Total 122 4 126 
 
Chart 9. Blood transfusion 
 
In our study 4.1% of patients in AUR group needed blood transfusion due 
to persistent haematuria, whereas 1.9% of patients without AUR needed blood 
transfusion 
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Blood transfusion- Cross tabulation 
 
Blood transfusion Total 
 NO YES 
Group 
AUR 
Count 71 3 74 
% 95.9% 4.1% 100.0% 
Non AUR 
Count 51 1 52 
% 98.1% 1.9% 100.0% 
Total 122 4 126 
Percentage 96.8% 3.2% 100% 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .451a 1 .502   
Continuity Correctionb .024 1 .876   
Likelihood Ratio .479 1 .489   
Fisher's Exact Test    .642 .452 
Linear-by-Linear 
Association .448 1 .503 
  
N of Valid Casesb 126     
 
P value – 0.642 Difference between the need of blood transfusion 
between the two groups is not statistically significant as evidenced by the p 
value 
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Table 10.Post op UTI 
 No Yes Total 
With AUR 56 18 74 
Without AUR 50 2 52 
Total 106 20 126 
 
Chart 10. Post operative UTI 
 
In our study around one fourth of the patients that is 24.3% of patients in 
AUR group suffered from UTI after TURP. This was quiet low in patients 
without AUR, developed only in 3.9% 
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Post operative UTI 
Cross tabulation 
 
UTI- post op 
Total 
0 1 
Group 
AUR 
Count 56 18 74 
% within 
Group 
75.7% 24.3% 100.0% 
Non_AUR 
Count 50 2 52 
% within 
Group 
96.2% 3.8% 100.0% 
Total 
Count 106 20 126 
% within 
Group 
84.1% 15.9% 100.0% 
 
P value – 0.004 
Of the total patients post operative UTI occur in 15.9% of patients. 24.3% 
of patients who presented with urinary retention developed UTI after TURP, 
where as it occurred only in 3.8% of patients who presented without urinary 
retention. This difference was statistically significant as evidenced by the p 
value of 0.004. 
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Table 11 Sepsis 
 No Yes Total 
With AUR 73 1 74 
Without AUR 52 0 52 
Total 125 1 126 
 
Chart 11 Sepsis 
 
Only one patient in AUR group developed urosepsis following TURP 
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Sepsis group – Cross tabulation 
 
Sepsis Total 
 NO YES 
Group 
AUR 
Count 73 1 74 
% 98.6% 1.4% 100.0% 
Non AUR 
Count 52 0 52 
% 100% 0% 100.0% 
Total 125 1 126 
Percentage 99.2% 0.8% 100% 
 
Statistics 
 Value df Asymp. Sig. (2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square .708a 1 .400   
Continuity 
Correctionb .000 1 1.000   
Likelihood Ratio 1.070 1 .301   
Fisher's Exact Test    1.000 .587 
Linear-by-Linear 
Association .703 1 .402   
N of Valid Casesb 126     
 
P value – 1.00 Sepsis occurred in only one patient in the AUR group, who 
was appropriately treated with higher antibiotics. There was no sepsis incident 
in patients without AUR. 
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Table 12 Recatheterisation 
 No Yes Total 
With AUR 57 17 74 
Without AUR 50 2 52 
Total 107 19 126 
 
Chart 12 Recatheterisation 
 
Recatheterisation after catheter removal following TURP was quiet 
higher for patients who presented with AUR. 23.0% of patients in this group 
needed recatheterisation. This was low in patients without AUR.  
  
77.0% 
23.0% 
96.2% 
3.8% 
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
120.0%
NO YES
Recatheterisation by group 
AUR Non_AUR
65 
 
Recatheterisation group 
Cross tabulation 
 
Recatheterisation 
Total 
NO YES 
Group 
AUR 
Count 57 17 74 
% within 
Group 
77.0% 23.0% 100.0% 
Non_AU
R 
Count 50 2 52 
% within 
Group 
96.2% 3.8% 100.0% 
Total 
Count 107 19 126 
% within 
Group 
85.0% 15.0% 100.0% 
 
P value 0.007   
Recatheterisation rate was 23.0% in AUR group, where as it was only 
3.8% in AUR minus group after TURP. This difference in recatheterisation rate 
was statistically significant as evidenced by the p value of 0.007 
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Table 13 Irritative LUTS 
 No Yes Total 
With AUR 56 18 74 
Without AUR 44 8 52 
Total 100 26 126 
 
Chart 13 LUTS 
 
18 patients in the AUR group developed irritative lower urinary tract 
symptoms like incontinence, increased frequency and urgency. In the AUR 
minus group only 8 patients developed irritative LUTS 
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LUTS group -Cross tabulation 
 
LUTS Total 
 NO YES 
Group 
AUR 
Count 56 18 74 
% 75.7% 24.3% 100.0% 
Non 
AUR 
Count 44 8 52 
% 84.6% 15.4% 100.0% 
Total 100 26 126 
Percentage 79.4% 20.6% 100% 
 
Statistics 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 1.490a 1 .222   
Continuity Correctionb .994 1 .319   
Likelihood Ratio 1.530 1 .216   
Fisher's Exact Test    .268 .159 
Linear-by-Linear 
Association 
1.478 1 .224 
  
 
P value0.319 
The difference between the two groups is not statistically significant as 
evidenced by p value as for as the irritative LUTS is concerned. 
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Table 14.  Lower urinary tract stricture 
 No Yes Total 
With AUR 72 2 74 
Without AUR 51 1 52 
Total 123 3 126 
 
Chart 14. Stricture
 
In our study 2 patients in AUR group and one patient in non AUR group 
developed stricture during 3 months of follow up 
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Stricture group- Cross tabulation 
 
Stricture Total 
 NO YES 
Group 
AUR 
Count 72 2 74 
% 97.3% 2.7% 100.0% 
Non AUR 
Count 51 1 52 
% 98.1% 1.9% 100.0% 
Total 123 3 126 
Percentage 97.6% 2.4% 100% 
 
Statistics 
 
Value df 
Asymp. 
Sig. (2-
sided) 
Exact Sig. 
(2-sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square .080a 1 .777   
Continuity 
Correctionb .000 1 1.000 
  
Likelihood Ratio .082 1 .775   
Fisher's Exact Test    1.000 .631 
Linear-by-Linear 
Association .079 1 .778 
  
N of Valid Casesb 126     
 
P value – 1.000 statistically not significant 
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Table 15. Re surgery 
 No Yes Total 
With AUR 73 1 74 
Without AUR 52 0 52 
Total 125 1 126 
 
Chart 15 Resurgery 
 
In our study only one patient in AUR group required re surgery for clot 
retention 
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Resurgery group- Cross tabulation 
 
Resurgery Total 
 NO YES 
Group 
AUR 
Count 73 1 74 
% 98.6% 1.4% 100.0% 
Non 
AUR 
Count 52 0 52 
% 100% 0% 100.0% 
Total 125 1 126 
Percentage 99.2% 0.8% 100% 
 
Statistics 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-
Square 
.708a 1 .400 
  
Continuity 
Correctionb 
.000 1 1.000 
  
Likelihood Ratio 1.070 1 .301   
Fisher's Exact Test    1.000 .587 
 
P value – 1.000 not statistically significant 
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Table 16 Group statistics length of hospital stay 
 Group N Mean Std. Deviation P-value 
Lenth of 
stay 
AUR 74 7.00 1.579 
0.000 Non_AU
R 
52 4.56 .777 
   
Statistics 
 
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
 
 
 
Length of 
stay 
 F Sig. t df 
Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Equal 
variances 
assumed 
28.537 .000 10.302 124 .000 2.442 .237 1.973 2.912 
 
Length of hospital stay was statistically significant in our study as 
evidenced by the p value 0.000 
  
73 
 
Table 17  Group statistics of PVR and Q max 
 Group N Mean Std. Deviation P-value 
PVR 
AUR 74 14.31 2.970 
0.062 
Non_AUR 52 13.32 2.551 
Qmax 
AUR 74 19.22 1.485 
0.947 
Non_AUR 52 19.20 1.485 
 
Mean PVR in AUR and non AUR groups were 14.31 and 13.32 ml 
respectively. There is no much difference between these two groups as for as 
the PVR is concerned. So it is not statistically significant. 
Q max is also almost the same between these two groups. We excluded 
the patients who developed recurrent retention  
 
 
 
 
 
74 
 
 
Bar chart shows the comparisons of all variables. 
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Master table comparing all variables with p value 
Sr .no Variables 
With AUR 
In % 
Without AUR 
In % 
P value 
1 HT 21.6 19.2 0.918 
2 DM 23.0 23.1 1.000 
3 IHD 10.8 9.6 1.000 
4 Volume(mean) 53.20ml 44.21 ml 0.000 
5 PSA(mean) 3.357 3.094 0.006 
6 TUR sundrome 1.4 0.0 1.00 
7 Haematuria 10.8 5.8 0.523 
8 Blood transfusion 4.1 1.9 0.642 
9 UTI – Post op 24.3 3.8 0.004 
10 Sepsis 1.4 0.0 1.000 
11 Recatheterisation 23.0 3.8 0.007 
12 Irritative LUTS 24.3 15.4 0.319 
13 Stricture 2.7 1.9 1.000 
14 Re surgery 1.4 0.0 1.000 
15 Length of stay(mean) 7 4.56 0.000 
16 PVR(mean) 14.31 13.32 0.062 
17 Q max(mean) 19.22 19.20 0.947 
 
  
 
 
 
DISCUSSION 
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DISCUSSION 
Benign prostatic hyperplasia is a common urological problem affecting 
men in older age group. Acute urinary retention may be the presenting 
symptom.  The prevalence rate of AUR in men with BPH varies. In western 
countries, the incidence rate was lower, ranging from 20 to 40%. Where as in 
developing countries the rate was quiet higher, can reach even more than 50%.  
The reason for the increased incidence of AUR in men with BPH in developing 
countries is unawareness of the symptom of BPH, fear of surgery, and cost 
factors. Chen JS and Chang CH et al from Taiwan conducted a retrospective 
study and found that post TURP complications were more in patients who 
presented with acute urinary retention when compared to those who presented 
without retention. Sajjad Ahmed from post graduate institute from Lady reading 
hospital Peshawar, Pakistan conducted  a study  and found that the chance of 
post TURP complication are more with those patients who present with acute 
urinary retention . There are few more studies which found that the 
complication rates are more for the patients with acute urinary retention. The 
purpose of this study is to found that whether there is any difference in the Post 
TURP complications and outcome of surgery for BPH for patients with and 
without acute urinary retention in our population, so that we can prevent and 
make ourselves as well as the patient to get ready to tackle these complications 
and create awareness among people.  
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 In our study we enrolled 126 patients diagnosed as BPH with their 
symptoms, clinical examinations, uroflowmetry and USG. Of these 126 
patients, 74 presented with AUR and 52 present without retention. We 
compared the following factors of preoperative variables like age, presence of 
any co morbid illness, gland size, grade of the gland by DRE, serum PSA.  And 
post operative variables like haematuria, need for blood transfusion, UTI, 
sepsis, recatheterisation rate,  PVR, length of hospital stay, lower urinary tract 
stricture , re surgery rate, TUR syndrome, Q max. 
Age distribution 
In our study men aged between 40 to 70 years were included. Of these the 
mean age for men who presented with AUR was 62.51 and for men without 
AUR were 61.06. The p value for the mean age is 0.164 which was not 
significant. So both the groups are comparable with age. Study done by Kurita 
et al also showed that there is no statistical difference between these two groups 
based on age. Whereas other studies like Olmsted county study, Meigs et al 
study and the study done by Berges et al showed that AUR occur more common 
in older age group. 
Co-morbid illness 
Regarding the co morbid factors, HT occurs in 21.6% of patients with 
AUR and 19.2% of patients without AUR. The two groups are comparable as 
for as the HT is concerned as the p value is 0.91 which is not significant. DM 
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occurs is 23% of patients with AUR and in 23.1% of patients without AUR. The 
p value here is 1.000- Not significant. 10.8% of the patients with AUR and 
9.6% of patients without AUR had IHD with a P value of 1.000. So in our study 
both groups are comparable in co morbid illness. Few studies showed that 
presence of co morbid factors may be confounding factors. 
TUR syndrome  
Only one patient in the AUR group developed TUR syndrome 
immediately at the end of the procedure. It was suspected clinically and serum 
electrolytes were done which showed hyponatremia and it was corrected. No 
patients in AUR minus group developed this syndrome. 
Haematuria   
In our study10.8 % of patients with AUR and 5.8% of patients without 
AUR had persistent haematuria after TURP. The p value is 0.523 which is not 
significant. 
Jeng- Sheng- Chen et al study showed haematuria in 8.1% of patients with 
AUR and 7.4% of patients without AUR. Our study is more or less similar to 
this one. 
Mebust et al study showed haematuria and blood transfusion in 6.4%, 
Kuntz et al showed 2%, where as it was higher in a study done by Doll et al- 
22% 
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Blood transfusion 
Blood transfusion rate was 4.1% and 1.9 % for patients with and without 
AUR respectively with a p value of 0.642 which is not significant. 
Jeng- Sheng- Chen et al study showed blood transfusion rate of 3.2% and 1.5% 
for patients who presented with and without AUR. 
Post operative UTI 
We did urine culture and sensitivity for all our patients post operatively. 
In our study 24.3% of patient with AUR and only 3.9% of patients without 
AUR had UTI as documented by urine culture. These patients were given a 
course of culture specific antibodies. The occurrence of UTI is higher in patients 
with AUR with a p value of 0.004 which is significant. The reason for this 
increased occurrence of UTI may be due to prolonged catheterization and 
hospital stay in patients with AUR.  
Jeng- Sheng- Chen et al study reported the UTI rate as 18.6% in AUR 
group and 15.6% in AUR minus group. Mebust et al showed 3.9%, Borboroglu 
et al showed 4%, whereas it was quiet higher in Doll et al study which showed 
25% 
Sepsis 
In our study only one patient (1.4%) with AUR developed sepsis after 
TURP. No patient without AUR had sepsis.  Patient was treated intensively with 
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IV fluids and higher antibiotics. Jeng- Sheng- Chen et al study reported sepsis in 
1.4% only in patients with AUR group. Mebust et al and Haupt et al showed 
urosepsis in 0.2% of patients after TURP. Doll et al showed 3% urosepsis. 
Recatheterisation  
In our study 23% of patients with AUR developed urinary retention after 
catheter removal in TURP, which was quiet higher when compared to 3.8% of 
patients without AUR. This is statistically significant with a p value of 0.007. If 
the patient develops urinary retention, we will recatheterise the patient and put 
him on alpha blocker and give trial void after 1 week. All of our patients 
responded well in trial voiding. 
Jeng- Sheng- Chen et al study showed recatheterisation rate in 13.8% 
and 0% for patients with and without AUR respectively. Mebust et al has 6.5%, 
Doll et al 3% Borboroguli et al 7.1% recatheterisation rate after TURP. The 
reason for increased rate of recatheterisation in patients with AUR may be due 
to hypoactive detrusor after chronic obstruction, inadequate resection due to 
increased gland size, or early cessation of procedure due to patient factor. 
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LUTS 
18 (24.3%) patients in the AUR group developed irritative lower urinary 
tract symptoms like incontinence, increased frequency and urgency. In the AUR 
minus group only 8(15.4%) patients developed irritative LUTS. P value0.319 
The difference between the two groups is not statistically significant as 
evidenced by p value as for as the irritative LUTS is concerned 
Lower urinary tract stricture 
In our study totally 3 patients developed lower urinary tract stricture 
2(2.7%) in the AUR arm and 1(1.9%) in the non AUR arm. This was diagnosed 
2 to 3 months after TURP, when the patient c/o thin stream and strain to void. 
We did AUG for these patients and diagnosed the stricture. We advised optical 
internal urethrotomy for these patients. These 3 patients were not willing for 
urethrotomy; hence dilatation was done. The reasons for the stricture formation 
may be due to instrumental injury, diathermy injury during TURP or due to 
prolonged catheterization. 
Jeng- Sheng- Chen et al study showed 2.6% and 3.2% for patients with 
and without AUR. 
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Re surgery 
Only one patient (1.4%) in our study developed clot retention. 
Cystoscopic clot evacuation was attempted, which could not be possible. Then 
open surgical evacuation was done and prostatic fossa was packed. The pack 
was removed after 2days, bleeding has stopped. 
Mean length of hospital stay  
It was 7 and 4.56 days for patients with and without AUR. This was 
statistically significant.  
Post operative PVR 
Mean post operative PVR for patients with and without AUR was 
14.31ml and 13.32 ml respectively. The p value was 0.062 which was not 
significant statistically. 
Q max 
We did Uroflow for all of our patients who voided after TURP to 
compare the flow pattern of urine.  The mean Q max was 19.22ml/sex and 
19.20ml/sec for patient with and without AUR. The p value is 0.947 which was 
not significant. 
  
  
 
 
       
CONCLUSION 
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CONCLUSIONS 
Our study is a prospective observational analytical study to compare the 
post TURP complication and outcome of patients with and without AUR. Our 
study clearly shows that post TURP complications like persistent haematuria, 
blood transfusion rate, post op UTI, sepsis, recatheterisation, lower urinary tract 
stricture, resurgery, TUR syndrome, length of hospital stay were higher in 
patients who presented with AUR than patients without AUR. Of these 
complications, post TURP UTI, recatheterisation rate and length of hospital stay 
were statistically significant in AUR group when compared to AUR minus 
group. So it is better to intervene earlier before the patients develop AUR in 
order to minimize the complications and to maximize the outcome. 
 
  
  
 
 
       
BIBLIOGRAPHY 
 
 
 
 
 
84 
 
BIBLIOGRAPHY 
1.  Reynard JM, Yang Q, Donovan JL, et al. The ICS- ‘‘BPH’’ Study: 
uroflowmetry, lower urinary tract symptoms and bladder outlet 
obstruction. Br J Urol 1998;82:619–23. 
2. Botker-Rasmussen I, Bagi P, Balslev Jorgensen J. Is bladder outlet 
obstruction normal in elderly men without lower urinary tract symptoms? 
NeurourolUrodyn1999;18:545–52. 
3. Hutchison A, Farmer R, Chapple C, et al. Characteristics ofpatients 
presenting with LUTS/BPH in six European countries.Eur Urol 
2006;50:555–62 
4. Briganti A, Capitanio U, Suardi N et al. Benign Prostatic Hyperplasia and 
Its Aetiologies. European Urology Supplements 2009; 8:865–871 
5. McConnell, J. D., Barry M. J., Bruskewitz R. E. et al: Benign Prostatic 
Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline, No 8.  
6. Tan et al., 2003b. Tan AH, Gilling PJ, Kennett KM, et al: A randomized 
trial comparing holmium laser enucleation of the prostate with TURP in 
large glands (40 to 200 grams). J Urol 2003; 170:1270-1274. 
7. Westenberg A, Gilling P, Kennett K, et al: Holmium laser resection of the 
prostate versus transurethral resection of the prostate: Results of a 
randomized trial with 4-year minimum long-term follow-up. J Urol 2004; 
172:616-619. 
85 
 
8. Costello et al., 1992. Costello AJ, Bowsher WG, Bolton DM, et al: Laser 
ablation of the prostate in patients with benign prostatic hypertrophy. Br J 
Urol 1992; 69:603-608.  
9. Costello and Crowe, 1994. Costello AJ, Crowe MR: A single institution 
experience of reflecting laser fiber over 4 years. J Urol 1994; 152:229A.  
10. Costello et al., 1994. Costello AJ, Shaffer BS, Crowe MR: Second 
generation delivery options for laser prostatic ablation. Urology 1994; 
43:262-266 
11. Emberton M , Anson K . Acute urinary retention in men: an age old 
problem . BMJ 1999 ; 318 : 921 – 5 
12. Choong S, Emberton M. Acute urinary retention . B JU Int 2000; 8 5 : 
186 – 201 
13. Murray K, Massey A, Feneley RC . Acute urinary retention – a 
urodynamic assessment . B r J Urol 1984 ; 56 : 468 – 73 
14. Armitage JN, Sibanda N, Cathcart PJ, Emberton M, van der Meulen JH. 
Mortality in men admitted to hospital with acute urinary retention: 
database analysis . B MJ 2007; 3 35 : 1199 – 202 
15. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral 
prostatectomy. Immediate and postoperative complications. J Urol 1989; 
141 : 243 – 7 
86 
 
16. Pickard R, Emberton M, Neal DE. The management of men with acute 
urinary retention. National Prostatectomy Audit Steering Group. B r J 
Urol 1998; 8 1 : 712 – 20 
17. Loh SY , Chin CM . A demographic profile of patients undergoing TURP 
for BPH  and presenting in acute urinary retention. BJU Int 2002; 89: 531 
– 3  
18. Malone PR, Cook A, Edmonson R, Gill MW, Shearer RJ. Prostatectomy: 
patients’ perception and long-term follow-up. B r J Urol 1988; 6 1 : 234 – 
8 
19. Cunha, 1976. Cunha GR: Epithelial-stromal interactions in development 
of the urogenital tract. Int Rev Cytol 1976; 47:137-194. 
20. Epstein, 1989. Epstein JI: The prostate and seminal vesicles. In: 
Sternberg SS, ed. Diagnostic Surgical Pathology, New York: Raven; 
1989:1393-1432 
21. Myers, 1991. Myers RP: Male urethral sphincteric anatomy and radical 
prostatectomy. Urol Clin North Am 1991; 18:211-227. Myers, 1994. 
22. Myers RP: Radical prostatectomy: Pertinent surgical anatomy. Atlas Urol 
Clin North Am 1994; 2:1-18. 
23. Tanagho, 1992. Tanagho EA: Anatomy of the lower urinary tract. In: 
Campbell's Urology, 6th ed.. Philadelphia: WB Saunders; 1992:40-69. 
87 
 
24. McNeal, 1972. McNeal JE: The prostate and prostatic urethra: A 
morphologic synthesis. J Urol 1972; 107:1008-1016.  
25. McNeal, 1988. McNeal JE: Normal histology of the prostate. Am J Surg 
Pathol 1988; 12:619-633 
26. Flocks, 1937. Flocks RH: The arterial distribution within the prostate 
gland: Its role in transurethral prostatic resection. J Urol 1937; 37:524-
548. 
27. Hinman, 1993. Hinman Jr F: Atlas of Urosurgical Anatomy, Philadelphia, 
WB Saunders, 1993. 
28. Oelrich, 1980. Oelrich TM: The urethral sphincter in the male. Am J Anat 
1980; 158:229-246.  
29. Oelrich, 1983. Oelrich TM: The striated urogenital sphincter muscle in 
the female. Anat Rec 1983; 205:223-232. 
30. Coffey DS. The molecular biology, endocrinology, and physiology of the 
prostate and seminal vesicles. In: Walsh PC, Retik AB, Stamey TA, 
31. Grayhack JT. Changes with aging in human seminal vesicle fluid fructose 
concentration and seminal vesicle w eight. J Urol. 1961;86:142–8 
32. Cunha G, Wang YZ, Hayw ard SW, Risbridger GP. Estrogenic effects on 
prostatic differentiation and carcinogenesis. Reprod Fertil Dev. 
2001;13:285–96.  
88 
 
33. Ho SM. Estrogens and anti-estrogens: Key mediators of prostate 
carcinogenesis and new therapeutic candidates. J Cell Biochem. 
2004;91:491–503.  
34. Harkonen PL, Makela SI. Role of estrogens in development of prostate 
cancer. J Steroid Biochem Mol Biol. 2004;92:297–305 
35. Sorensen BS, Torring N, Bor MV, Nexo E. Quantitation of the mRNA 
expression of the epidermal growth factor Clin Med. 2000;136:209–17. 
36 Moore RA. Inflammation of the prostate gland. J Urol. 1937;38:173–82. 
37. Taguchi O, Kojima A, Nishizuka Y. Experimental autoimmune prostatitis 
after neonatal thymectomy in the mouse. Clin Ep Immunol 1985;60:123–
9.  
38. Taguchi O, Nishizuka Y. Self tolerance and localised autoimmunity; 
Mouse models of autoimmune disease that suggest tissue-specific 
suppressor T cells are involved in self tolerance. J Ep Med. 1987;165: 
39. Lee Keith L, Peehl Donna M. Molecular and cellular pathogenesis of 
benign prostatic hyperplasia. J Urol. 2004;172:1784–91. 
40. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: 
Age-related tissueremodeling. Ep Gerontol. 2005;40:121–8. 
41. Kramer G, Marberger M. Could Inflammation be a key component in the 
progression of benign prostatic hyperplasia? Curr Opin in Urol.2006; 
16:25 
89 
 
42. Shapiro E, Hartanto V, Lepor H. 1992. The response to alpha blockade in 
BPH is related to the percent area density of smooth muscle. Prostate 21: 
297-307 
43. Franks, 1976. Franks L: Benign prostatic hypertrophy: Gross and 
microscopic anatomy. U.S. Department of Health, Education, and 
Welfare NIH Publication No. 76-1113-63, 1976. 
44. Lin et al., 2001. Lin VK, Benaim EA, McConnell JD: Alpha-blockade 
down regulates myosin heavy chain gene expression in human benign 
prostatic hyperplasia. Urology 2001; 57:170-175 
45. Isaacs J, Coffey DS. Etiology and disease process of benign prostatic 
hyperplasia. Prostate.1987; 2 (suppl):33-50 
46. Elliot SJ, Zorn BH, McLeod DG, Moul JW, Nyberg L, Striker LJ, Striker 
GE. Prostate Cancer Prostatic Dis. 2003; 6(2):138-42. 
47. Levin RM, Haugaard N, O'Connor L, Buttyan R, Das A, Dixon JS, 
Gosling JA. Neurourol Urodyn. 2000; 19(5):609-29 
48. Reilly, N. J. (2000). Assessment and management of acute or transient 
urinary incontinence In D. B. Doughty (Red.), Urinary & Fecal 
Incontinence. (2nd ed.). (pp. 47-61). St. Lousi, USA. Mosby 
49. Rhodes T, Girman CJ, Jacobsen SJ, et al. Longitudinal prostate growth 
rates during 5 years in randomly selected community men 40-79 years 
old. J Urol. 1999; 161:1174-1179 
90 
 
50. Abrams P. New words for old: lower urinary tract symptoms for    
“prostatism”. BMJ 1994; 308:929-930. 
51. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U,van 
Kerrebroeck P, Victor A, Wein A. The Standardisation of terminology of 
lower urinary tract function: Urology 2003;61:37-49. 
52. Michel F, Dubruille T, Cercueil J-P, Paparel P, Cognet F, Krause D. 
Arterial embolization for massive hematruria following transurethral 
prostatectomy. J Urol 2002;168: 2550–2. 
53. Theodorou C, Moutzouris G, Floratos D, Plastiras D, Katsifotis C, 
Mertziotis N. Incontinence after surgery for benign prostatic hypertrophy: 
the case for complex approach and treatment. Eur Urol 1998; 33:370 
54. Wasson JH, Reda DJ, Bruskewitz RC, Ellison J, Kelly N, M Henderson 
WG for the Veterans affairs cooperative study grosup on transurethral 
resection of the prostate. N Engl J Med 1995; 322: 75–9.  
55. Campbell- Walsh urology 10th edition 
 
 
  
 
 
         
ANNEXURES 
 
 
 
 
 

ANNEXURE: 2 
 
 
PROFORMA 
 
NAME:      AGE:    SEX: 
 
ADDRESS:         IP.NO: 
 
D.O.A:     D.O.S:      D.O.D: 
 
PRESENTING COMPLAINTS: 
 
H/O AUR 
 
IPSS SCORE: 
 
GENERAL EXAMINATION: 
 
 P.R:     B.P: 
 
PER ABDOMEN: 
 
PER RECTAL: 
 
INVESTIGATIONS: 
HB%:    PCV% 
 
BLOOD:  UREA- SUGAR SERUM CREATININE-  
 
Sr ELECTROLYTES    Sr PSA 
 
URINE C/S: 
 
USG KUB: PROSTATE SIZE:  PVR 
 
UROFLOW:  Qmax:  AFR:   Voided Volume: 
 
CYSTOSCOPY: 
 
Presence of lateral and median lobes – Grade 
 
Presence of intravesical extension  Length of prostatic urethra 
 
  
OPERATIVE PROCEDURE: 
 
Operative time: Irrigation: 
 
POST OP.PERIOD: 
 
CATHETER REMOVAL: 
 
USG: 
 
FOLLOW UP: 
 
IPSS SCORE: 
 
UROFLOW:   Qmax  AFR  Voided Volume 
 
BIOPSY  
 
ANNEXURE 3
  
 
 
 
MASTER CHART 
  
Serial No
Name
Age
IP NO
Institution
HT
DM
IHD
Volume-CC
DRE
PSA
TUR                            
syndrome
hematuia
Blood                                                                        
transfusion
UTI-                                                                                                
post op
sepsis
Re                          
catheterisatio
LUTS
stricture
resurgery
Lenth of stay
PVR
Q max
1
M
r.A
nn
am
al
ai
50
14
22
03
3
K
M
C
H
0
0
0
58
2
3.
2
0
0
0
1
0
1
1
0
0
8
25
18
2
R
aj
en
di
ra
n
54
14
22
16
0
K
M
C
H
0
0
0
54
2
3.
1
0
0
0
0
0
0
0
0
0
5
18
19
3
M
r.S
rin
iv
as
an
58
14
22
76
0
K
M
C
H
0
0
0
54
2
3.
7
0
0
0
1
0
0
0
0
0
8
14
20
4
th
ul
si
do
ss
68
14
22
79
0
K
M
C
H
0
0
0
52
2
3.
9
0
0
0
0
0
0
0
0
0
7
10
19
5
M
r.A
ru
m
ug
am
65
14
22
81
3
K
M
C
H
1
0
1
52
2
3.
9
0
0
0
0
0
1
0
0
0
6
14
19
6
M
r.K
an
na
iy
an
59
14
26
51
0
K
M
C
H
1
1
0
59
2
3.
6
0
0
0
1
0
1
0
0
0
8
16
19
7
K
up
pu
sa
m
y
53
14
26
98
1
K
M
C
H
0
0
0
51
2
2.
8
0
0
0
0
0
0
0
0
0
5
11
19
8
M
r.P
ar
as
ur
am
an
61
14
27
40
4
K
M
C
H
0
1
0
53
2
4
0
0
0
0
0
0
1
0
0
6
13
21
9
M
r.L
og
an
at
ha
n
50
14
27
63
8
K
M
C
H
0
0
0
60
2
3.
9
0
0
0
0
0
1
0
0
0
6
13
22
10
A
an
an
dh
an
56
14
27
71
2
K
M
C
H
0
0
0
56
2
3.
1
0
0
0
0
0
0
0
0
0
5
17
18
11
M
r.V
ar
ad
ha
n
60
14
27
71
5
K
M
C
H
1
1
0
60
2
4.
2
0
0
0
0
0
0
0
0
0
6
14
19
12
M
rJ
oh
n 
Pr
ak
as
h
68
14
29
12
4
K
M
C
H
1
1
1
58
2
4
1
1
1
1
0
1
0
1
1
10
12
17
13
K
up
pa
nn
an
61
14
29
82
3
K
M
C
H
0
0
0
52
2
3.
1
0
0
0
0
0
0
0
0
0
7
18
20
14
M
r.K
ar
up
pa
n
63
14
35
12
7
K
M
C
H
0
0
0
54
2
3.
2
0
0
0
0
0
0
1
0
0
7
14
21
15
M
r.P
on
na
n
67
14
35
04
8
K
M
C
H
0
0
0
48
1
3.
6
0
0
0
0
0
1
0
0
0
6
16
19
16
G
an
es
ha
n
59
14
35
12
7
K
M
C
H
0
0
0
48
1
2.
2
0
0
0
0
0
0
0
0
0
7
14
18
17
M
r.B
al
as
ub
ra
m
an
ia
n
68
14
35
97
8
K
M
C
H
0
0
0
52
2
4.
2
0
0
0
1
0
0
0
0
0
8
12
20
18
M
r.R
am
an
59
14
36
12
3
K
M
C
H
1
1
0
58
2
3.
9
0
0
0
0
0
0
1
0
0
6
13
21
19
Si
va
ra
m
an
67
14
36
42
3
K
M
C
H
0
0
0
54
2
3.
1
0
0
0
0
0
1
0
0
0
7
12
20
20
M
r.K
up
pu
sa
m
y
57
14
36
82
3
K
M
C
H
0
0
0
49
2
3.
2
0
0
0
1
0
0
0
0
0
9
14
21
21
M
r.C
ho
tti
la
l
69
14
37
27
0
K
M
C
H
1
1
0
54
2
3.
9
0
0
0
0
0
1
0
0
0
5
16
19
22
D
av
id
65
14
37
29
8
K
M
C
H
0
0
0
52
2
2.
9
0
0
0
0
0
0
0
0
0
7
12
19
23
M
r.P
an
ch
at
ch
ar
am
63
14
37
32
8
K
M
C
H
0
1
1
49
2
3.
4
0
0
0
0
0
0
0
0
0
5
14
18
24
M
r.R
aj
en
di
ra
n
65
14
37
43
9
K
M
C
H
0
0
0
57
2
3.
7
0
0
0
0
0
1
0
1
0
8
20
17
M
A
ST
E
R
 C
H
A
R
T
 -W
IT
H
 A
U
R
25
M
r.T
ik
ka
ra
m
69
14
37
61
9
K
M
C
H
0
0
0
56
2
3.
8
0
1
0
1
0
0
1
0
0
9
12
17
26
M
r.V
ee
ra
m
an
i
69
14
40
73
5
K
M
C
H
0
0
0
56
2
2.
4
0
0
0
0
0
0
0
0
0
5
20
21
27
M
un
iy
an
59
14
40
76
8
K
M
C
H
0
0
0
60
2
3.
9
0
0
0
0
0
1
0
0
0
6
19
20
28
M
r.P
an
ne
er
59
14
40
80
0
K
M
C
H
0
0
0
48
2
2.
9
0
0
0
1
0
0
0
0
0
8
17
19
29
R
am
as
am
y
68
14
40
81
0
K
M
C
H
0
0
0
46
1
2.
1
0
0
0
0
0
1
0
0
0
6
13
18
30
M
r.P
en
ic
ill
ay
a
70
14
40
82
5
K
M
C
H
1
1
1
40
1
3.
2
0
0
0
0
0
0
1
0
0
10
12
21
31
M
r.D
av
id
68
14
40
98
5
K
M
C
H
0
0
0
49
2
3.
1
0
0
0
1
0
1
0
0
0
9
14
20
32
K
ai
la
sa
m
59
18
53
0
G
R
H
0
0
0
54
2
3.
5
0
0
0
0
0
0
0
0
0
8
12
21
33
M
r.D
ha
st
ha
gi
ri
66
18
68
6
G
R
H
0
1
1
58
2
3.
5
0
1
0
1
0
0
0
0
0
10
14
19
34
R
am
an
48
18
70
1
G
R
H
0
0
0
51
2
2.
3
0
0
0
0
0
0
0
0
0
7
15
18
35
M
r.P
on
nu
sa
m
y
69
18
58
9
G
R
H
0
0
0
48
1
3.
1
0
0
0
0
0
0
1
0
0
8
13
19
36
K
an
na
n
65
18
72
1
G
R
H
0
0
0
52
1
2.
9
0
0
0
0
0
0
0
0
0
7
18
21
37
M
r.S
w
ap
an
 m
an
da
l
53
18
73
4
G
R
H
1
0
1
58
2
3.
9
0
0
0
1
0
1
0
0
0
9
12
19
38
M
r.S
ub
ba
iy
an
58
18
79
0
G
R
H
0
0
0
54
2
3.
1
0
0
0
0
0
0
0
0
0
8
17
18
39
G
an
es
ha
n
59
18
83
4
G
R
H
0
0
0
52
2
3.
5
0
0
0
0
0
0
0
0
0
8
15
19
40
M
r.K
an
ni
ap
pa
n
68
18
88
4
G
R
H
0
0
0
50
2
3.
1
0
0
0
0
0
0
1
0
0
6
13
21
41
M
r.L
og
an
at
ha
n
63
19
13
0
G
R
H
0
0
0
49
2
2.
9
0
0
0
0
0
0
0
0
0
6
16
18
42
V
ija
ya
n
61
20
07
8
G
R
H
0
0
0
48
2
3.
7
0
0
0
0
0
0
0
0
0
6
14
19
43
N
az
ee
r
58
20
23
4
G
R
H
0
0
0
54
2
3.
1
0
0
0
0
0
0
0
0
0
7
18
20
44
C
hi
nn
ay
an
65
20
45
6
G
R
H
0
0
0
58
2
3.
6
0
0
0
0
0
0
0
0
0
8
16
17
45
K
an
na
pp
an
61
20
96
8
G
R
H
0
0
0
53
2
3.
1
0
0
0
0
0
0
0
0
0
5
16
18
46
M
r.B
irb
al
52
21
69
7
G
R
H
0
0
0
60
3
4.
1
0
0
0
0
0
0
1
0
0
5
10
21
47
M
r.T
ha
ng
ar
aj
u
58
21
89
0
G
R
H
1
1
1
58
2
3.
2
0
1
1
1
0
1
0
0
0
10
14
19
48
M
r.S
el
va
ra
j
67
21
92
9
G
R
H
0
0
0
56
2
3.
6
0
0
0
0
0
0
0
0
0
8
11
20
49
G
an
ap
at
hy
59
22
34
5
G
R
H
0
0
0
49
2
3.
1
0
0
0
0
0
0
0
0
0
5
10
18
50
Th
iru
pp
at
hi
67
22
45
6
G
R
H
0
0
0
60
2
4.
1
0
0
0
0
0
0
0
0
0
6
13
19
51
V
is
w
an
at
ha
n
59
22
86
7
G
R
H
0
0
0
57
2
3.
2
0
0
0
0
0
0
0
0
0
5
12
21
52
Su
re
nd
ra
n
56
23
45
3
G
R
H
0
0
0
49
2
2.
9
0
0
0
0
0
0
0
0
0
7
14
17
53
Sa
ra
va
na
n
65
23
97
0
G
R
H
0
0
0
54
2
3.
4
0
0
0
0
0
0
0
0
0
6
13
16
54
M
r.S
el
va
ra
j
62
24
17
8
G
R
H
0
0
0
51
2
3.
2
0
0
0
0
0
0
1
0
0
5
11
21
55
M
r.P
al
an
i
65
24
89
0
G
R
H
1
1
1
57
2
3.
9
0
0
0
0
0
0
0
0
0
5
12
20
56
M
r.M
an
i
68
25
10
1
G
R
H
1
1
0
60
2
3.
9
0
1
0
1
1
0
1
0
0
10
14
18
57
M
r.S
ub
ra
m
an
i
70
25
33
9
G
R
H
0
0
0
52
2
3.
4
0
0
0
0
0
0
0
0
0
4
16
17
58
M
r.G
ov
in
dh
an
67
25
42
0
G
R
H
0
0
0
59
2
3.
7
0
0
0
0
0
0
1
0
0
8
15
21
59
M
r.V
as
u
68
25
58
7
G
R
H
0
0
0
54
2
4
0
0
0
1
0
0
0
0
0
10
21
16
60
M
r.K
an
dh
as
am
y
67
25
62
1
G
R
H
1
1
0
54
2
3.
8
0
0
0
0
0
0
0
0
0
6
20
21
61
M
r.K
an
ni
ap
pa
n
62
25
67
8
G
R
H
0
0
0
40
1
2.
7
0
1
0
0
0
0
1
0
0
5
13
18
62
M
r.R
am
as
am
y
65
25
87
9
G
R
H
1
1
0
54
2
3.
2
0
0
0
0
0
0
0
0
0
6
12
18
63
M
r.G
ov
in
da
ra
j
64
26
54
5
G
R
H
0
0
0
56
2
3.
7
0
0
0
1
0
1
0
0
0
9
14
19
64
M
r.K
ris
hn
an
68
26
56
2
G
R
H
1
1
0
51
2
3.
1
0
0
0
0
0
0
1
0
0
8
11
21
65
M
rK
an
na
iy
an
57
26
42
1
G
R
H
0
0
0
48
2
3.
1
0
0
0
0
0
0
0
0
0
6
12
20
66
M
r.R
aj
en
di
ra
n
65
26
45
0
G
R
H
1
1
0
58
2
3.
2
0
1
1
0
0
1
0
0
0
8
14
21
67
M
r.P
un
ni
ya
m
oo
rth
y
60
26
42
9
G
R
H
1
1
0
52
2
3.
6
0
0
0
1
0
0
1
0
0
8
17
18
68
M
r.r
am
as
am
y
65
26
57
9
G
R
H
0
0
0
53
2
3.
1
0
0
0
0
0
0
1
0
0
7
15
20
69
M
r.K
an
na
pp
an
66
26
68
0
G
R
H
0
0
0
49
2
2.
8
0
0
0
0
0
0
0
0
0
6
10
17
70
M
r.P
on
nu
sa
m
y
65
26
83
1
G
R
H
0
0
0
48
2
3.
3
0
0
0
0
0
0
0
0
0
6
11
19
71
M
r.D
ur
ai
sa
m
y
69
26
83
0
G
R
H
0
0
0
56
2
3.
9
0
1
0
1
0
1
0
0
0
9
14
21
72
M
r.T
hu
ls
id
as
s
68
26
85
9
G
R
H
0
0
0
49
2
3.
2
0
0
0
0
0
0
1
0
0
5
16
21
73
M
r.T
he
nn
av
an
58
26
98
7
G
R
H
0
0
0
53
2
3.
1
0
0
0
1
0
0
1
0
0
9
14
20
74
R
aj
an
64
27
12
5
G
R
H
0
0
0
52
2
2.
4
0
0
0
0
0
0
0
0
0
8
12
18
1-
 y
es
 
0-
 N
o 
Sr.NO
Name
Age
IP NO
Hospital
HT
DM
IHD
Volume
DRE
PSA
TUR                                                                               
syndrome
hematuria
Blood                             
transfusion
Post op                        
UTI
sepsis
Re                      
catheterisation
luts
stricture
Re                       
surgery
Length of stay
PVR
Q max
1
M
r.V
el
m
ur
ug
an
55
14
25
31
4
K
M
C
H
0
0
0
42
1
3.
4
0
0
0
0
0
0
0
0
0
4
14
20
2
M
r.G
an
es
ha
n
69
14
25
37
0
K
M
C
H
0
0
0
44
2
3.
3
0
0
0
0
0
0
0
0
0
5
11
19
3
M
r.K
an
ni
ap
pa
n
50
14
23
88
9
K
M
C
H
0
0
0
40
1
2.
8
0
0
0
0
0
0
0
0
0
4
8
17
4
M
r F
ra
nc
is
70
14
26
61
0
K
M
C
H
0
0
0
43
2
3.
3
0
0
0
0
0
0
0
0
0
4
9
18
5
M
R
.K
ris
hn
an
66
14
26
67
2
K
M
C
H
0
0
0
42
2
3.
2
0
0
0
0
0
0
0
0
0
4
10
21
6
M
r.S
ub
ra
m
an
i
65
14
29
39
8
K
M
C
H
1
1
1
52
2
2.
9
0
0
0
0
0
0
1
0
0
5
12
22
7
M
R
.M
oo
rth
y
57
14
29
62
1
K
M
C
H
0
0
0
38
1
2.
2
0
0
0
0
0
0
0
0
0
4
15
19
8
M
r.N
ar
ay
an
an
70
14
32
06
3
K
M
C
H
0
0
0
40
1
3.
3
0
0
0
0
0
0
0
0
0
4
12
18
9
M
r.J
ey
al
al
48
48
14
31
13
8
K
M
C
H
0
0
0
38
1
2.
8
0
0
0
0
0
0
1
0
0
4
13
20
10
M
r.R
am
es
h
55
14
33
34
8
K
M
C
H
0
0
0
49
2
3.
3
0
0
0
0
0
0
0
0
0
5
14
18
11
M
r.K
ar
ee
m
 B
ai
60
14
33
55
0
K
M
C
H
0
0
0
49
2
3.
2
0
0
0
0
0
0
0
0
0
4
18
17
12
M
r.G
an
es
h 
48
14
33
64
7
K
M
C
H
1
0
0
52
2
2.
4
0
0
0
0
0
0
0
0
0
5
17
19
13
M
r.S
ad
ai
ya
pp
an
46
14
33
52
1
K
M
C
H
0
1
0
45
2
3.
2
0
0
0
0
0
0
0
0
0
4
11
18
14
M
r.K
ris
hn
am
oo
rth
y
54
14
33
59
0
K
M
C
H
1
0
0
43
2
3.
9
0
0
0
0
0
0
1
0
0
5
14
21
15
M
r.P
er
um
al
60
14
34
15
6
K
M
C
H
0
0
0
36
1
2.
1
0
0
0
0
0
0
0
0
0
4
13
22
16
M
r.P
on
m
ut
ha
n
66
14
35
06
1
K
M
C
H
0
0
0
40
1
3.
2
0
0
0
0
0
0
0
0
0
5
15
19
17
M
r.P
er
um
al
61
14
37
78
1
K
M
C
H
0
1
0
42
2
2.
9
0
0
0
0
0
0
0
0
0
4
11
17
18
M
r.G
op
al
an
62
14
37
83
9
K
M
C
H
0
0
1
40
2
3.
4
0
0
0
0
0
0
0
0
0
5
12
20
19
M
r.G
un
al
an
58
14
38
59
1
K
M
C
H
0
0
0
52
2
2.
6
0
0
0
0
0
0
1
0
0
4
14
19
20
M
r.R
am
ac
ha
nd
ra
n
69
14
31
33
7
K
M
C
H
0
1
0
40
1
3.
5
0
0
0
0
0
0
0
0
0
5
12
21
21
M
r.K
an
na
pp
an
67
14
31
47
8
K
M
C
H
0
0
0
48
2
3.
2
0
0
0
0
0
0
0
0
0
4
20
19
22
M
r.A
na
nd
ha
n
68
14
32
40
3
K
M
C
H
0
0
0
45
2
3.
2
0
0
0
0
0
0
0
0
0
4
16
17
23
M
r.K
up
pa
n
57
14
32
50
1
K
M
C
H
0
0
0
46
2
3.
9
0
0
0
0
0
0
0
0
0
5
13
20
24
M
r.T
ha
ng
ar
aj
65
14
33
81
1
K
M
C
H
0
0
0
56
2
4
0
1
0
0
0
1
0
1
0
6
14
19
M
A
ST
E
R
 C
H
A
R
T
 - 
W
IT
H
 O
U
T
 A
U
R
25
M
r.A
bd
ul
 re
hm
an
66
14
33
98
0
K
M
C
H
0
0
0
38
1
3.
1
0
0
0
0
0
0
0
0
0
4
12
21
26
M
r.K
as
in
at
ha
n 
55
14
34
07
6
K
M
C
H
1
0
1
46
2
3.
8
0
0
0
0
0
0
1
0
0
5
12
17
27
M
rN
ar
ay
an
an
64
14
30
42
0
K
M
C
H
1
1
0
43
1
3.
3
0
0
0
0
0
0
0
0
0
5
20
19
28
M
r.R
am
an
58
14
30
65
1
K
M
C
H
0
0
0
48
2
3.
1
0
0
0
0
0
0
1
0
0
5
12
18
29
M
r.B
ab
u
70
13
29
0
G
R
H
1
0
0
47
2
3.
2
0
0
0
0
0
0
0
0
0
5
15
21
30
M
r.K
an
na
n
60
14
58
0
G
R
H
0
0
0
50
2
3.
9
0
1
0
0
0
0
0
0
0
6
12
20
31
M
r.K
um
ar
an
58
14
67
1
G
R
H
0
0
0
48
2
3.
2
0
0
0
0
0
0
0
0
0
5
16
18
32
M
r.B
al
an
57
14
71
2
G
R
H
0
0
0
38
1
2.
1
0
0
0
0
0
0
0
0
0
4
12
19
33
M
r.K
ar
un
ak
ar
an
67
15
21
3
G
R
H
1
1
0
42
2
3.
2
0
0
0
0
0
0
0
0
0
5
13
20
34
Si
va
ne
sa
n
65
15
65
8
G
R
H
0
0
0
38
1
2.
3
0
0
0
0
0
0
0
0
0
4
14
19
35
M
r.S
rin
iv
as
an
65
16
52
9
G
R
H
0
0
0
46
2
3.
5
0
0
0
0
0
0
0
0
0
5
12
18
36
M
r.H
ab
ee
b 
re
hm
an
65
18
01
6
G
R
H
1
1
1
47
1
3.
3
0
0
0
1
0
0
1
0
0
7
14
21
37
M
r.M
ur
ug
es
an
53
18
59
3
G
R
H
0
0
0
54
2
3.
9
0
1
1
0
0
1
0
0
0
6
13
20
38
M
r.V
is
w
an
at
ha
n
56
18
57
7
G
R
H
1
0
0
50
2
3.
1
0
0
0
0
0
0
0
0
0
4
13
18
39
M
r.A
ro
ki
ya
m
65
20
14
9
G
R
H
0
1
0
38
1
2.
7
0
0
0
0
0
0
0
0
0
4
12
21
40
M
r.G
un
as
ek
ar
an
53
21
39
7
G
R
H
0
0
0
43
2
3.
2
0
0
0
0
0
0
0
0
0
5
16
19
41
M
r.B
ha
sk
ar
an
64
21
92
4
G
R
H
0
1
0
50
2
3.
8
0
0
0
1
0
0
0
0
0
7
9
20
42
M
r.S
el
va
ra
j
64
21
93
0
G
R
H
0
0
0
38
1
2.
1
0
0
0
0
0
0
0
0
0
4
11
21
43
M
r.R
am
ac
ha
nd
ra
n
66
21
84
7
G
R
H
0
0
0
43
1
3.
2
0
0
0
0
0
0
0
0
0
4
12
19
44
M
r.N
al
lia
h
55
21
92
1
G
R
H
0
1
1
50
2
3.
8
0
0
0
0
0
0
0
0
0
4
15
18
45
M
r.E
zh
um
al
ai
60
22
48
9
G
R
H
0
0
0
38
1
2.
1
0
0
0
0
0
0
0
0
0
4
14
20
46
M
r.B
al
as
ub
ra
m
an
ia
n
60
28
32
0
G
R
H
0
0
0
47
2
4
0
0
0
0
0
0
0
0
0
4
12
16
47
M
r.K
an
na
n
57
28
37
8
G
R
H
0
1
0
38
1
2.
2
0
0
0
0
0
0
0
0
0
4
18
21
48
M
r.K
ub
er
an
69
28
39
7
G
R
H
1
0
0
43
2
3.
2
0
0
0
0
0
0
0
0
0
4
16
18
49
M
r.R
am
ak
ris
ha
na
n
69
28
34
2
G
R
H
0
1
0
55
2
3.
7
0
0
0
0
0
0
0
0
0
4
12
19
50
M
r.A
bd
ul
 k
ha
de
r
65
28
35
0
G
R
H
0
0
0
39
1
2.
1
0
0
0
0
0
0
1
0
0
4
11
20
51
R
aj
en
di
ra
n
61
28
37
0
G
R
H
0
0
0
40
1
2.
6
0
0
0
0
0
0
0
0
0
4
13
21
52
M
r.k
an
na
n
62
28
36
8
G
R
H
0
0
0
40
1
2
0
0
0
0
0
0
0
0
0
4
14
17
1-
 y
es
 
0-
 N
o 
A
N
N
E
U
X
R
E 
5 
